# Real-world efficacy and safety of TYSABRI SC vs. IV

Keywords: TYSABRI, subcutaneous, intravenous, multiple sclerosis, efficacy, safety, relapse rate, EDSS, natalizumab

> This page provides an analysis of the real-world efficacy and safety of subcutaneous (SC) versus intravenous (IV) administration of TYSABRI (natalizumab) in patients with highly active relapsing-remitting multiple sclerosis (MS).

## Details
- [Introduction](#): Overview of TYSABRI as a disease-modifying therapy (DMT) for multiple sclerosis, including its mechanism of action and approval for SC administration.
- [Methods and Materials](#): Description of the retrospective study design, including data extraction from an MS patient database starting in November 2021.
- [Results](#): Key findings showing comparable efficacy and safety between SC and IV TYSABRI, with relapse rates and EDSS scores maintained over 12 months.
- [Conclusions](#): Summary of the study's implications, highlighting the comparable outcomes of SC and IV TYSABRI and the need for further long-term studies.
- [Adverse Event Reporting](#): Information on how healthcare professionals in the UK and Ireland can report adverse events related to TYSABRI.